This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to semaglutide through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription medication.
For decades, the standard of care for obesity treated weight as a behavioral problem. Eat less, move more. The framing was simple, and for most people it was insufficient. Appetite is not a matter of willpower — it is regulated by hormones, and those hormones respond to specific pharmacological targets.
Semaglutide is a GLP-1 receptor agonist that works on one of those targets with precision. Here is the mechanism, what the STEP and SELECT trial programs demonstrated, and what the clinical evidence actually supports.
Key Takeaways
- Regulatory Status: FDA-approved for type 2 diabetes as Ozempic in 2017 and Rybelsus oral in 2019, for chronic weight management as Wegovy in 2021, and for reduction of cardiovascular events in adults with overweight or obesity and established cardiovascular disease under the Wegovy SELECT indication in 2024.
- Research Stage: Approved and extensively studied across the SUSTAIN (T2D), STEP (obesity), and SELECT (cardiovascular) trial programs
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: Ozempic — DailyMed · Wegovy — DailyMed · Rybelsus (oral) — DailyMed
- How it works: Activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve glucose-dependent insulin secretion.
- What the research shows: The STEP 1 trial (N=1,961; semaglutide 2.4 mg weekly vs placebo; adults with obesity without T2D) demonstrated 14.9% mean weight loss versus 2.4% with placebo at 68 weeks, and the SELECT trial (N=17,604; semaglutide 2.4 mg weekly vs placebo; median 39.8 months) showed a 20% reduction in major cardiovascular events (HR 0.80; 95% CI 0.72–0.90).
What Is Semaglutide?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a modified analog of GLP-1(7-37), a 31-amino-acid peptide, that shares approximately 94% structural homology with endogenous GLP-1. It was developed by Novo Nordisk and first approved by the FDA in December 2017 for type 2 diabetes management under the brand name Ozempic. It activates GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract, producing glucose-dependent insulin secretion, reduced glucagon release, slowed gastric emptying, and centrally mediated appetite suppression. Its extended plasma half-life of approximately 164 hours enables once-weekly subcutaneous dosing or daily oral dosing, depending on formulation.
Semaglutide is structurally modified from endogenous GLP-1 with an albumin-binding fatty acid side chain, which substantially extends its half-life by reducing renal clearance and protecting against enzymatic degradation. Three branded formulations are FDA-approved: subcutaneous Ozempic (T2D and cardiovascular risk reduction), subcutaneous Wegovy (weight management and cardiovascular risk reduction), and oral Rybelsus (T2D). A baseline assessment of blood sugar and insulin sensitivity is typically part of clinical evaluation before initiation.
All randomized controlled trial data cited in this article were generated using FDA-approved branded formulations of semaglutide (Ozempic, Wegovy, Rybelsus). Real-world observational studies cited may include patients prescribed compounded formulations. Efficacy and safety findings from branded-formulation trials may not be directly transferable to compounded formulations.
What Semaglutide May Support
1. Weight Reduction in Adults With Obesity
The STEP 1 trial published in the New England Journal of Medicine in 2021 by Wilding and colleagues remains the landmark weight trial for semaglutide. The trial enrolled 1,961 participants with obesity or overweight with at least one weight-related comorbidity but no type 2 diabetes over 68 weeks. Semaglutide 2.4 mg once weekly produced a mean weight reduction of 14.9% compared to 2.4% with placebo. Individual results varied substantially. The STEP 5 trial published in Nature Medicine in 2022 by Garvey and colleagues, following 304 adults with obesity or overweight without T2D receiving semaglutide 2.4 mg once weekly over 104 weeks, confirmed durable weight reduction of 15.2% versus 2.6% with placebo over two years of continuous therapy. The STEP 4 trial published in JAMA in 2021 by Rubino and colleagues enrolled 803 adults with obesity or overweight without T2D who received semaglutide 2.4 mg weekly during a 20-week run-in; from week 20 to 68, participants who continued semaglutide lost an additional 7.9% of body weight, while those switched to placebo regained 6.9%. Weight regain after discontinuation is well-documented: in STEP 4, participants who switched to placebo regained approximately two-thirds of prior weight loss within 52 weeks. This finding is material to understanding the ongoing nature of therapy. Metabolic and weight-related biomarkers provide the objective baseline for tracking response over time.
2. Glycemic Control in Type 2 Diabetes
The SUSTAIN clinical trial program evaluated subcutaneous semaglutide across multiple T2D populations. In the SUSTAIN FORTE trial published in the Lancet Diabetes and Endocrinology in 2021 by Frias and colleagues, 961 adults with inadequately controlled T2D (baseline HbA1c 8.0–10.0%) on stable metformin were followed over 40 weeks; semaglutide 2.0 mg reduced HbA1c by 2.2 percentage points and body weight by 6.9 kg versus 1.9 percentage points and 6.0 kg with semaglutide 1.0 mg, confirming a dose-response effect on glycemia. A 2023 meta-analysis of 17 RCTs pooling 14,940 patients in Diabetology and Metabolic Syndrome by Hu and colleagues found that subcutaneous semaglutide 1.0 mg reduced HbA1c by a mean 1.36 percentage points versus placebo (95% CI −1.59 to −1.13) with no increase in serious adverse events, confirming it as an effective and well-tolerated once-weekly T2D option across diverse populations. Oral semaglutide (Rybelsus) has a bioavailability of approximately 1% or less of the subcutaneous dose, requiring fasting-state administration for consistent absorption; a 2024 real-world analysis of 242 T2D patients in Acta Diabetologica by Conti and colleagues found 12-month persistence of 72.3% with oral semaglutide versus 92.4% with the subcutaneous formulation, indicating substantially lower adherence with the daily tablet. Monitoring HbA1c at baseline and at 12 to 24 weeks of therapy quantifies glycemic response. Reference ranges vary by lab and individual; providers interpret results in clinical context.
3. Cardiovascular Risk Reduction
The SELECT trial published in the New England Journal of Medicine in 2023 by Lincoff and colleagues is among the most clinically significant findings in the GLP-1 RA class. SELECT enrolled 17,604 adults aged 45 or older with BMI ≥27, pre-existing atherosclerotic cardiovascular disease, and no type 2 diabetes over a mean follow-up of 39.8 months — making it the first GLP-1 RA trial to demonstrate cardiovascular benefit independent of diabetes status. Semaglutide 2.4 mg once weekly reduced the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke) by 20% compared to placebo (HR 0.80; 95% CI 0.72–0.90; P<0.001). A SELECT sub-analysis of 4,286 participants with heart failure published in the Lancet in 2024 by Deanfield and colleagues found that semaglutide reduced MACE in both HFrEF (HR 0.65; 95% CI 0.49–0.87) and HFpEF (HR 0.69; 95% CI 0.51–0.91) subgroups. A 2025 SELECT sub-analysis published in the Lancet by Deanfield and colleagues found that an estimated 33% of the MACE benefit was mediated through waist circumference reduction (HR 0.86; 95% CI 0.77–0.97 after adjustment for time-varying waist circumference changes). Cardiovascular health biomarkers including lipid panels, blood pressure, and hs-CRP are relevant baseline and monitoring markers for this indication.
4. Metabolic Marker Improvements
According to a 2023 meta-analysis of 6 RCTs pooling 3,962 adults with overweight or obesity without diabetes in Diabetes, Obesity and Metabolism by Qin and colleagues, semaglutide 2.4 mg produced a mean body-weight reduction of 11.80% versus placebo (95% CI −12.93 to −10.68) and a waist circumference reduction of 9.4 cm (95% CI −10.1 to −8.8), with significant improvements in blood pressure, fasting blood glucose, HbA1c, CRP, and lipid parameters. The reduction in hs-CRP — a sensitive systemic inflammation marker — is notable because it suggests anti-inflammatory effects beyond those explained by weight loss alone. A 2021 narrative review in Trends in Cardiovascular Medicine by Chao and colleagues summarized that semaglutide 2.4 mg once weekly, as demonstrated in the STEP 1 trial (N=1,961; adults with BMI ≥30 or ≥27 with comorbidities, without T2D), achieves approximately 15% weight loss versus 2.4% with placebo at 68 weeks through appetite suppression, improved satiety, and reduced preference for energy-dense foods, reflecting central GLP-1 receptor activity in the hypothalamus. Triglycerides and HDL cholesterol are among the lipid markers most responsive to semaglutide therapy.
5. Weight Loss With Behavioral Intervention
The STEP 3 trial published in JAMA in 2021 by Wadden and colleagues enrolled 611 adults with overweight or obesity without T2D over 68 weeks and evaluated semaglutide 2.4 mg combined with intensive behavioral therapy. Mean weight reduction was 16.0% in the semaglutide plus intensive behavioral therapy group versus 5.7% for placebo plus intensive behavioral therapy. The STEP 8 trial published in JAMA in 2022 by Rubino and colleagues enrolled 338 adults with overweight or obesity without T2D over 68 weeks and compared semaglutide 2.4 mg once weekly head-to-head with liraglutide 3.0 mg once daily: semaglutide produced significantly greater weight loss (15.8% vs. 6.4% with liraglutide; difference −9.4 percentage points; P<0.001), establishing semaglutide as the more effective option within the GLP-1 RA class at tested doses. These findings reflect complementary effects of pharmacological appetite regulation and structured behavioral support.
Semaglutide vs. Tirzepatide: Key Differences
Semaglutide activates GLP-1 receptors only; tirzepatide activates both GLP-1 and GIP receptors. This mechanistic difference is reflected in comparative efficacy data: in the SURMOUNT-1 trial (N=2,539; 72 weeks; adults with obesity without T2D), tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight reductions of 15.0%, 19.5%, and 20.9% versus 3.1% with placebo, compared with 14.9% versus 2.4% with placebo for semaglutide 2.4 mg in STEP 1 (N=1,961; 68 weeks).
Semaglutide has a substantially more extensive cardiovascular outcome evidence base. The SELECT trial (N=17,604; semaglutide 2.4 mg weekly vs placebo; mean 39.8 months) demonstrated a 20% MACE reduction (HR 0.80; 95% CI 0.72–0.90) in non-diabetic patients with BMI ≥27 and established cardiovascular disease — a finding that has not yet been replicated for tirzepatide in a dedicated outcome trial of comparable size and duration. Tirzepatide's cardiovascular outcome trial (SURMOUNT-MMO) is ongoing. A real-world observational study of 172,382 T2D patients with elevated cardiovascular risk published by Kruger and colleagues in Nature Medicine in 2026 found no significant difference in cardiovascular outcomes between tirzepatide and semaglutide at one year (HR 1.06; 95% CI 0.95–1.18 for the composite of MI, stroke, or all-cause mortality), suggesting comparable cardiovascular benefits, though this is observational evidence requiring confirmation in dedicated outcome trials.
Semaglutide is available in three FDA-approved formulations: subcutaneous once-weekly injection (Ozempic, Wegovy), and oral daily tablet (Rybelsus). Tirzepatide is available only as a subcutaneous once-weekly injection. For individuals who prefer or require an oral option, semaglutide is currently the only FDA-approved choice within the GLP-1 RA class, though oral bioavailability is substantially lower than injectable. Comparative claims involving specific doses, populations, and study designs should be interpreted with attention to those variables. A licensed provider evaluates which compound is appropriate based on individual clinical profile.
Semaglutide Formulations
Three FDA-approved semaglutide formulations are available. Subcutaneous Ozempic (0.5 mg, 1.0 mg, 2.0 mg once weekly) is approved for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established cardiovascular disease. Subcutaneous Wegovy (0.25 mg escalating to 2.4 mg once weekly) is approved for chronic weight management and, following the SELECT trial, for reduction of cardiovascular events in adults with overweight or obesity and established cardiovascular disease without T2D. Oral Rybelsus (3 mg escalating to 14 mg daily) is approved for type 2 diabetes. Oral bioavailability is approximately 0.66% of the subcutaneous dose; it must be taken fasting with a small amount of water and requires a 30-minute wait before eating or drinking. Compounded injectable semaglutide has been available through 503A pharmacies; compounding eligibility is subject to current FDA regulatory requirements, and providers should confirm current compounding status. Compounded medications are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been evaluated by the FDA for safety, efficacy, or quality in the same manner as commercially manufactured branded products. Compounded semaglutide may differ from the branded version in formulation, concentration, and inactive ingredients.
Biomarkers to Monitor With Semaglutide
A licensed provider will determine appropriate monitoring. The following biomarkers are clinically relevant given semaglutide's mechanism and therapeutic effects:
- HbA1c: The primary glycemic monitoring marker for T2D and prediabetes management. Meaningful reductions are typically observed at 12 to 24 weeks of therapy. Baseline and follow-up HbA1c values quantify glycemic response. Reference ranges vary by lab and clinical context.
- Fasting glucose: A shorter-horizon glycemic marker than HbA1c. Useful at baseline to characterize glycemic status and at follow-up to track incremental changes. Fasting glucose is particularly informative in individuals in the prediabetes range (100-125 mg/dL).
- Fasting insulin: Semaglutide improves insulin sensitivity alongside direct effects on beta-cell insulin secretion. Baseline fasting insulin characterizes insulin resistance and provides context for subsequent glycemic changes.
- Lipid panel (LDL-C, triglycerides, HDL-C, non-HDL-C): Meta-analysis of STEP trials documents improvements in triglycerides, blood pressure, and lipid profiles alongside weight reduction. Baseline lipid assessment and follow-up at 3 to 6 months capture these cardiometabolic effects.
- hs-CRP: A sensitive systemic inflammation marker. Meta-analysis by Qin et al. (2023) documented significant reductions in hs-CRP with semaglutide 2.4 mg, suggesting anti-inflammatory effects beyond weight loss. Relevant for individuals with elevated baseline inflammatory status and cardiovascular risk.
- Complete metabolic panel (CMP): Covers liver function (AST, ALT) and kidney function (creatinine, BUN, eGFR). Semaglutide may produce modest improvements in eGFR in individuals with early renal impairment; baseline assessment is standard before initiation. An increased rate of biliary disease has been observed with weight loss and GLP-1 RA use; liver function monitoring is standard clinical practice.
- Complete blood count (CBC): Relevant at baseline to characterize overall health status and rule out underlying conditions that may affect tolerability assessment, including anemia, which can present with fatigue overlapping with common GI side effects.
- Blood pressure: STEP trial data document consistent reductions in systolic blood pressure alongside weight reduction. Tracking blood pressure before and during therapy quantifies this cardiometabolic effect, particularly relevant in the SELECT population with established cardiovascular disease.
- Thyroid function (TSH): GLP-1 receptor agonists carry a class-wide boxed warning regarding thyroid C-cell tumors observed in rodent studies. Baseline thyroid assessment may be relevant in individuals with pre-existing thyroid conditions or family history that warrants monitoring.
HbA1c, fasting glucose, fasting insulin, and a lipid panel are the core markers for evaluating cardiometabolic baseline before starting semaglutide. A complete metabolic panel confirms organ function. For individuals with established cardiovascular disease or elevated risk, a comprehensive cardiovascular biomarker assessment provides additional context that is particularly relevant given semaglutide's SELECT trial cardiovascular indication.
What Semaglutide Is Typically Prescribed For
Providers typically evaluate candidates for semaglutide based on FDA-approved indications: type 2 diabetes requiring glycemic management (Ozempic, Rybelsus); chronic weight management in adults with BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (Wegovy); and reduction of serious cardiovascular events in adults with established cardiovascular disease and overweight or obesity without T2D (Wegovy, SELECT indication). Baseline bloodwork confirming glycemic status, lipid profile, and organ function is standard practice before initiation. Semaglutide requires a prescription from a licensed provider.
Who Should Not Use Semaglutide
A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny based on the FDA prescribing information:
- Personal or family history of medullary thyroid carcinoma (MTC), as GLP-1 receptor agonists are associated with thyroid C-cell tumors in rodent studies; a boxed warning is required in all semaglutide prescribing information
- Multiple endocrine neoplasia syndrome type 2 (MEN 2), which includes elevated risk of MTC
- Known hypersensitivity to semaglutide or any component of the formulation; serious hypersensitivity reactions, including anaphylaxis, have been reported
- Pregnancy, as semaglutide may cause fetal harm based on animal data; adequate contraception is recommended during use and for a period following discontinuation per provider guidance
- Severe gastrointestinal disease, including gastroparesis, as semaglutide slows gastric emptying and may worsen underlying motility disorders
- History of pancreatitis, as GLP-1 receptor agonists have been associated with acute pancreatitis; while a direct causal relationship has not been conclusively established, the prescribing information advises caution and monitoring
- Diabetic retinopathy requiring treatment, as rapid glycemic improvement has been associated with early worsening of retinopathy in some patients
Side Effects and Safety Considerations
The most common side effects of semaglutide are gastrointestinal and are generally dose-dependent and most prominent during dose escalation. A safety analysis of the SELECT trial population published by Kushner and colleagues in Obesity in 2025, covering 17,604 participants receiving semaglutide 2.4 mg weekly or placebo over a mean of 39.8 months, found that serious adverse events were less frequent with semaglutide than placebo (33.4% vs 36.4%) while treatment discontinuation due to adverse events was higher with semaglutide (16.6% vs 8.2%, primarily driven by GI tolerability), confirming a favorable risk-benefit profile with no new safety concerns over nearly 40 months of follow-up.
Common (reported in clinical studies):
- Nausea (most common; a pooled analysis of STEP 1–3 participants receiving semaglutide 2.4 mg weekly reported nausea in 43.9% versus 16.1% with placebo, predominantly during dose escalation)
- Diarrhea (29.7% with semaglutide 2.4 mg vs 15.9% with placebo in the pooled STEP 1–3 analysis)
- Vomiting (24.5% with semaglutide 2.4 mg vs 6.3% with placebo in the pooled STEP 1–3 analysis)
- Constipation (24.2% with semaglutide 2.4 mg vs 11.1% with placebo in the pooled STEP 1–3 analysis)
- Injection-site reactions, including bruising, erythema, and pruritus at the injection site (mild and typically transient)
- Decreased appetite (a primary mechanism of action; expected and reported across trials)
- Abdominal pain and dyspepsia
Less common but reported:
- Acute pancreatitis: discontinue and contact your provider promptly if you experience severe, persistent abdominal pain radiating to the back
- Cholelithiasis (gallstones): an increased rate of biliary disease has been observed with weight loss and GLP-1 RA use; alert provider to right upper quadrant pain or jaundice
- Hypoglycemia: primarily in individuals using concurrent insulin or sulfonylureas; risk is low with semaglutide monotherapy
- Psychiatric symptoms: pharmacovigilance data published by Tobaiqy and colleagues in the International Journal of Clinical Pharmacy in 2024 reported psychiatric adverse events in 1.2% of all reports across GLP-1 RA class, with depression most common; alert provider to mood changes
- Hair loss (telogen effluvium): associated with rapid weight loss rather than direct drug effect; generally self-limiting within 3 to 6 months
- Increased heart rate: a modest increase in resting heart rate (approximately 2-4 bpm) has been observed across GLP-1 RA class; clinical significance in most patients is uncertain
Is Semaglutide Legal?
As of April 2026, semaglutide is FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management and cardiovascular risk reduction in adults with obesity and established cardiovascular disease (Wegovy). Semaglutide is not FDA-approved for any other indications. The safety and efficacy of semaglutide for any use other than the approved indications have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
Compounded semaglutide has been available through 503A pharmacies. The FDA removed semaglutide from the shortage list in 2025, which changed the regulatory landscape for compounding of this compound under Section 503A and 503B. As of April 2026, providers should confirm current compounding status and regulatory requirements. Compounded semaglutide is not FDA-approved and has not undergone FDA review for safety, efficacy, or manufacturing quality. It is not available over the counter in any formulation.
Semaglutide does not appear on the 2026 WADA Prohibited List. Its approved indications are metabolic and cardiovascular, and it is not associated with athletic performance enhancement in the pharmacological sense covered by anti-doping regulations.
Understanding Your Baseline Before Starting Semaglutide
Semaglutide's effects on glycemia, weight, and cardiovascular risk markers are measurable — but only if there is a baseline to measure against. HbA1c and fasting glucose establish where glycemic control sits before therapy. Fasting insulin characterizes the degree of insulin resistance. A lipid panel captures the cardiometabolic context that determines whether the SELECT cardiovascular indication is clinically relevant. A metabolic panel rules out contraindications. Without these reference points, changes at 12, 24, and 52 weeks are interpretable only in isolation — not in the context of where the individual started.
That principle is central to Superpower's approach to preventive health: the belief that objective biomarker data should come before any clinical decision, and that every change during therapy should be interpretable against a documented baseline.
Frequently Asked Questions
What is the difference between semaglutide and tirzepatide?
Semaglutide activates GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP receptors. Tirzepatide has produced greater mean weight reduction and HbA1c lowering than semaglutide in comparative analyses at studied doses. Semaglutide has more extensive dedicated cardiovascular outcome trial data, including the SELECT trial (N=17,604). Both compounds carry similar gastrointestinal side effect profiles. The prescribing decision depends on individual clinical factors, indication, and provider evaluation.
Is semaglutide the same as Ozempic?
Ozempic is a brand-name subcutaneous formulation of semaglutide (0.5 mg, 1.0 mg, 2.0 mg once weekly) approved for type 2 diabetes and cardiovascular risk reduction in T2D patients. Wegovy is a higher-dose subcutaneous semaglutide formulation (escalating to 2.4 mg weekly) approved for weight management and cardiovascular risk reduction in adults with obesity without T2D. Rybelsus is an oral semaglutide tablet approved for type 2 diabetes. All three contain the same active molecule; they differ in dose, route, and FDA indication.
What happens to your body when you stop semaglutide?
Weight regain is well-documented after discontinuation. In the STEP 1 trial extension following 327 participants who discontinued semaglutide 2.4 mg weekly after 68 weeks, participants regained 11.6 percentage points of lost weight — approximately two-thirds of the initial reduction — within 52 weeks of stopping treatment, and most cardiometabolic improvements also reversed. This reflects the ongoing hormonal nature of GLP-1 pathway modulation; the effects are not permanent. Providers typically discuss long-term maintenance strategies before initiating therapy.
How much weight can you lose on semaglutide in 3 months?
In the STEP 1 trial (N=1,961), participants taking semaglutide 2.4 mg once weekly achieved 14.9% mean weight reduction over 68 weeks versus 2.4% with placebo; weight loss was progressive throughout the treatment period, with the majority occurring between weeks 12 and 68 during dose escalation and maintenance. The trial did not report a standalone 12-week interim analysis, and early results during the dose-escalation phase may not reflect the full treatment effect. Individual results varied substantially across trial participants. Dietary and lifestyle changes concurrent with medication use were part of the trial protocol.
Can you take semaglutide without being diabetic?
Yes. Semaglutide (as Wegovy) is FDA-approved for chronic weight management in adults without type 2 diabetes who have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. The STEP 1 trial specifically enrolled participants without T2D and demonstrated 14.9% mean weight loss at 68 weeks. Additionally, the SELECT trial enrolled non-diabetic adults with established cardiovascular disease and overweight or obesity, supporting the 2024 cardiovascular risk reduction indication for Wegovy.
Is compounded semaglutide the same as brand-name?
No. Compounded semaglutide is not FDA-approved and has not undergone FDA review for quality, potency, or sterility. Compounded medications are prepared by a licensed compounding pharmacy and may differ from branded formulations in formulation, concentration, and inactive ingredients. The FDA removed semaglutide from the shortage list in February 2025, which changed the regulatory landscape for compounding. A licensed provider can clarify current regulatory status and available options.
Does semaglutide cause hair loss?
Hair thinning associated with semaglutide is attributed to what research suggests is telogen effluvium, a diffuse shedding response to significant physiological stress, including rapid weight loss. It is not considered a direct pharmacological drug effect. It was reported at low rates in STEP trial data. Telogen effluvium is generally self-limiting and resolves within 3 to 6 months as body weight stabilizes. Adequate protein intake and overall nutritional adequacy during weight loss are clinically relevant to minimize hair follicle disruption.
Is semaglutide FDA-approved?
Yes. Semaglutide is FDA-approved under three brand names for four indications: Ozempic for type 2 diabetes (2017) and cardiovascular risk reduction in T2D patients with established heart disease (2020); Rybelsus (oral) for type 2 diabetes (2019); and Wegovy for chronic weight management (2021) and for reducing serious cardiovascular events in adults with obesity and established cardiovascular disease without T2D under the 2024 SELECT indication. No other uses have been approved by the FDA.
IMPORTANT SAFETY INFORMATION
Semaglutide is an FDA-approved prescription medication marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral, type 2 diabetes). The compounded formulation available through Superpower is NOT the FDA-approved drug product. Compounded semaglutide has not been reviewed by the FDA for safety, efficacy, or manufacturing quality. Clinical trial results cited on this page were generated using FDA-approved branded formulations and may not apply to compounded versions. The availability of compounded semaglutide is subject to ongoing regulatory developments regarding drug shortage status. Superpower is a technology platform that connects you with licensed providers and pharmacies; Superpower does not prescribe or dispense medications.
Boxed warning (from FDA-approved labeling): Semaglutide causes thyroid C-cell tumors in rodents. It is unknown whether it causes medullary thyroid carcinoma (MTC) in humans. Do not use if you or any family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use if you: have a personal or family history of MTC or MEN 2; have had a serious allergic reaction to semaglutide.
Warnings: pancreatitis, gallbladder events, hypoglycemia (with insulin/sulfonylureas), kidney injury, serious allergic reactions, diabetic retinopathy complications, gastroparesis/delayed gastric emptying, suicidal ideation (reported with GLP-1 medications).
Common side effects: nausea, vomiting, diarrhea, stomach pain, constipation, fatigue, headache.
Pregnancy: not recommended. Discontinue at least 2 months before a planned pregnancy.
Not a complete list of risks. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.
This article is for informational purposes only and does not constitute medical advice. Superpower Health facilitates access to semaglutide through licensed providers and compounding pharmacy partners. Always consult a qualified healthcare provider before starting any prescription medication.
For decades, the standard of care for obesity treated weight as a behavioral problem. Eat less, move more. The framing was simple, and for most people it was insufficient. Appetite is not a matter of willpower — it is regulated by hormones, and those hormones respond to specific pharmacological targets.
Semaglutide is a GLP-1 receptor agonist that works on one of those targets with precision. Here is the mechanism, what the STEP and SELECT trial programs demonstrated, and what the clinical evidence actually supports.
Key Takeaways
- Regulatory Status: FDA-approved for type 2 diabetes as Ozempic in 2017 and Rybelsus oral in 2019, for chronic weight management as Wegovy in 2021, and for reduction of cardiovascular events in adults with overweight or obesity and established cardiovascular disease under the Wegovy SELECT indication in 2024.
- Research Stage: Approved and extensively studied across the SUSTAIN (T2D), STEP (obesity), and SELECT (cardiovascular) trial programs
- Availability: Prescription only through Superpower's licensed provider network and compounding pharmacy partners
- Prescribing information: Ozempic — DailyMed · Wegovy — DailyMed · Rybelsus (oral) — DailyMed
- How it works: Activates GLP-1 receptors to suppress appetite, slow gastric emptying, and improve glucose-dependent insulin secretion.
- What the research shows: The STEP 1 trial (N=1,961; semaglutide 2.4 mg weekly vs placebo; adults with obesity without T2D) demonstrated 14.9% mean weight loss versus 2.4% with placebo at 68 weeks, and the SELECT trial (N=17,604; semaglutide 2.4 mg weekly vs placebo; median 39.8 months) showed a 20% reduction in major cardiovascular events (HR 0.80; 95% CI 0.72–0.90).
What Is Semaglutide?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a modified analog of GLP-1(7-37), a 31-amino-acid peptide, that shares approximately 94% structural homology with endogenous GLP-1. It was developed by Novo Nordisk and first approved by the FDA in December 2017 for type 2 diabetes management under the brand name Ozempic. It activates GLP-1 receptors in the pancreas, hypothalamus, and gastrointestinal tract, producing glucose-dependent insulin secretion, reduced glucagon release, slowed gastric emptying, and centrally mediated appetite suppression. Its extended plasma half-life of approximately 164 hours enables once-weekly subcutaneous dosing or daily oral dosing, depending on formulation.
Semaglutide is structurally modified from endogenous GLP-1 with an albumin-binding fatty acid side chain, which substantially extends its half-life by reducing renal clearance and protecting against enzymatic degradation. Three branded formulations are FDA-approved: subcutaneous Ozempic (T2D and cardiovascular risk reduction), subcutaneous Wegovy (weight management and cardiovascular risk reduction), and oral Rybelsus (T2D). A baseline assessment of blood sugar and insulin sensitivity is typically part of clinical evaluation before initiation.
All randomized controlled trial data cited in this article were generated using FDA-approved branded formulations of semaglutide (Ozempic, Wegovy, Rybelsus). Real-world observational studies cited may include patients prescribed compounded formulations. Efficacy and safety findings from branded-formulation trials may not be directly transferable to compounded formulations.
What Semaglutide May Support
1. Weight Reduction in Adults With Obesity
The STEP 1 trial published in the New England Journal of Medicine in 2021 by Wilding and colleagues remains the landmark weight trial for semaglutide. The trial enrolled 1,961 participants with obesity or overweight with at least one weight-related comorbidity but no type 2 diabetes over 68 weeks. Semaglutide 2.4 mg once weekly produced a mean weight reduction of 14.9% compared to 2.4% with placebo. Individual results varied substantially. The STEP 5 trial published in Nature Medicine in 2022 by Garvey and colleagues, following 304 adults with obesity or overweight without T2D receiving semaglutide 2.4 mg once weekly over 104 weeks, confirmed durable weight reduction of 15.2% versus 2.6% with placebo over two years of continuous therapy. The STEP 4 trial published in JAMA in 2021 by Rubino and colleagues enrolled 803 adults with obesity or overweight without T2D who received semaglutide 2.4 mg weekly during a 20-week run-in; from week 20 to 68, participants who continued semaglutide lost an additional 7.9% of body weight, while those switched to placebo regained 6.9%. Weight regain after discontinuation is well-documented: in STEP 4, participants who switched to placebo regained approximately two-thirds of prior weight loss within 52 weeks. This finding is material to understanding the ongoing nature of therapy. Metabolic and weight-related biomarkers provide the objective baseline for tracking response over time.
2. Glycemic Control in Type 2 Diabetes
The SUSTAIN clinical trial program evaluated subcutaneous semaglutide across multiple T2D populations. In the SUSTAIN FORTE trial published in the Lancet Diabetes and Endocrinology in 2021 by Frias and colleagues, 961 adults with inadequately controlled T2D (baseline HbA1c 8.0–10.0%) on stable metformin were followed over 40 weeks; semaglutide 2.0 mg reduced HbA1c by 2.2 percentage points and body weight by 6.9 kg versus 1.9 percentage points and 6.0 kg with semaglutide 1.0 mg, confirming a dose-response effect on glycemia. A 2023 meta-analysis of 17 RCTs pooling 14,940 patients in Diabetology and Metabolic Syndrome by Hu and colleagues found that subcutaneous semaglutide 1.0 mg reduced HbA1c by a mean 1.36 percentage points versus placebo (95% CI −1.59 to −1.13) with no increase in serious adverse events, confirming it as an effective and well-tolerated once-weekly T2D option across diverse populations. Oral semaglutide (Rybelsus) has a bioavailability of approximately 1% or less of the subcutaneous dose, requiring fasting-state administration for consistent absorption; a 2024 real-world analysis of 242 T2D patients in Acta Diabetologica by Conti and colleagues found 12-month persistence of 72.3% with oral semaglutide versus 92.4% with the subcutaneous formulation, indicating substantially lower adherence with the daily tablet. Monitoring HbA1c at baseline and at 12 to 24 weeks of therapy quantifies glycemic response. Reference ranges vary by lab and individual; providers interpret results in clinical context.
3. Cardiovascular Risk Reduction
The SELECT trial published in the New England Journal of Medicine in 2023 by Lincoff and colleagues is among the most clinically significant findings in the GLP-1 RA class. SELECT enrolled 17,604 adults aged 45 or older with BMI ≥27, pre-existing atherosclerotic cardiovascular disease, and no type 2 diabetes over a mean follow-up of 39.8 months — making it the first GLP-1 RA trial to demonstrate cardiovascular benefit independent of diabetes status. Semaglutide 2.4 mg once weekly reduced the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal MI, non-fatal stroke) by 20% compared to placebo (HR 0.80; 95% CI 0.72–0.90; P<0.001). A SELECT sub-analysis of 4,286 participants with heart failure published in the Lancet in 2024 by Deanfield and colleagues found that semaglutide reduced MACE in both HFrEF (HR 0.65; 95% CI 0.49–0.87) and HFpEF (HR 0.69; 95% CI 0.51–0.91) subgroups. A 2025 SELECT sub-analysis published in the Lancet by Deanfield and colleagues found that an estimated 33% of the MACE benefit was mediated through waist circumference reduction (HR 0.86; 95% CI 0.77–0.97 after adjustment for time-varying waist circumference changes). Cardiovascular health biomarkers including lipid panels, blood pressure, and hs-CRP are relevant baseline and monitoring markers for this indication.
4. Metabolic Marker Improvements
According to a 2023 meta-analysis of 6 RCTs pooling 3,962 adults with overweight or obesity without diabetes in Diabetes, Obesity and Metabolism by Qin and colleagues, semaglutide 2.4 mg produced a mean body-weight reduction of 11.80% versus placebo (95% CI −12.93 to −10.68) and a waist circumference reduction of 9.4 cm (95% CI −10.1 to −8.8), with significant improvements in blood pressure, fasting blood glucose, HbA1c, CRP, and lipid parameters. The reduction in hs-CRP — a sensitive systemic inflammation marker — is notable because it suggests anti-inflammatory effects beyond those explained by weight loss alone. A 2021 narrative review in Trends in Cardiovascular Medicine by Chao and colleagues summarized that semaglutide 2.4 mg once weekly, as demonstrated in the STEP 1 trial (N=1,961; adults with BMI ≥30 or ≥27 with comorbidities, without T2D), achieves approximately 15% weight loss versus 2.4% with placebo at 68 weeks through appetite suppression, improved satiety, and reduced preference for energy-dense foods, reflecting central GLP-1 receptor activity in the hypothalamus. Triglycerides and HDL cholesterol are among the lipid markers most responsive to semaglutide therapy.
5. Weight Loss With Behavioral Intervention
The STEP 3 trial published in JAMA in 2021 by Wadden and colleagues enrolled 611 adults with overweight or obesity without T2D over 68 weeks and evaluated semaglutide 2.4 mg combined with intensive behavioral therapy. Mean weight reduction was 16.0% in the semaglutide plus intensive behavioral therapy group versus 5.7% for placebo plus intensive behavioral therapy. The STEP 8 trial published in JAMA in 2022 by Rubino and colleagues enrolled 338 adults with overweight or obesity without T2D over 68 weeks and compared semaglutide 2.4 mg once weekly head-to-head with liraglutide 3.0 mg once daily: semaglutide produced significantly greater weight loss (15.8% vs. 6.4% with liraglutide; difference −9.4 percentage points; P<0.001), establishing semaglutide as the more effective option within the GLP-1 RA class at tested doses. These findings reflect complementary effects of pharmacological appetite regulation and structured behavioral support.
Semaglutide vs. Tirzepatide: Key Differences
Semaglutide activates GLP-1 receptors only; tirzepatide activates both GLP-1 and GIP receptors. This mechanistic difference is reflected in comparative efficacy data: in the SURMOUNT-1 trial (N=2,539; 72 weeks; adults with obesity without T2D), tirzepatide 5 mg, 10 mg, and 15 mg produced mean weight reductions of 15.0%, 19.5%, and 20.9% versus 3.1% with placebo, compared with 14.9% versus 2.4% with placebo for semaglutide 2.4 mg in STEP 1 (N=1,961; 68 weeks).
Semaglutide has a substantially more extensive cardiovascular outcome evidence base. The SELECT trial (N=17,604; semaglutide 2.4 mg weekly vs placebo; mean 39.8 months) demonstrated a 20% MACE reduction (HR 0.80; 95% CI 0.72–0.90) in non-diabetic patients with BMI ≥27 and established cardiovascular disease — a finding that has not yet been replicated for tirzepatide in a dedicated outcome trial of comparable size and duration. Tirzepatide's cardiovascular outcome trial (SURMOUNT-MMO) is ongoing. A real-world observational study of 172,382 T2D patients with elevated cardiovascular risk published by Kruger and colleagues in Nature Medicine in 2026 found no significant difference in cardiovascular outcomes between tirzepatide and semaglutide at one year (HR 1.06; 95% CI 0.95–1.18 for the composite of MI, stroke, or all-cause mortality), suggesting comparable cardiovascular benefits, though this is observational evidence requiring confirmation in dedicated outcome trials.
Semaglutide is available in three FDA-approved formulations: subcutaneous once-weekly injection (Ozempic, Wegovy), and oral daily tablet (Rybelsus). Tirzepatide is available only as a subcutaneous once-weekly injection. For individuals who prefer or require an oral option, semaglutide is currently the only FDA-approved choice within the GLP-1 RA class, though oral bioavailability is substantially lower than injectable. Comparative claims involving specific doses, populations, and study designs should be interpreted with attention to those variables. A licensed provider evaluates which compound is appropriate based on individual clinical profile.
Semaglutide Formulations
Three FDA-approved semaglutide formulations are available. Subcutaneous Ozempic (0.5 mg, 1.0 mg, 2.0 mg once weekly) is approved for type 2 diabetes management and cardiovascular risk reduction in adults with T2D and established cardiovascular disease. Subcutaneous Wegovy (0.25 mg escalating to 2.4 mg once weekly) is approved for chronic weight management and, following the SELECT trial, for reduction of cardiovascular events in adults with overweight or obesity and established cardiovascular disease without T2D. Oral Rybelsus (3 mg escalating to 14 mg daily) is approved for type 2 diabetes. Oral bioavailability is approximately 0.66% of the subcutaneous dose; it must be taken fasting with a small amount of water and requires a 30-minute wait before eating or drinking. Compounded injectable semaglutide has been available through 503A pharmacies; compounding eligibility is subject to current FDA regulatory requirements, and providers should confirm current compounding status. Compounded medications are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been evaluated by the FDA for safety, efficacy, or quality in the same manner as commercially manufactured branded products. Compounded semaglutide may differ from the branded version in formulation, concentration, and inactive ingredients.
Biomarkers to Monitor With Semaglutide
A licensed provider will determine appropriate monitoring. The following biomarkers are clinically relevant given semaglutide's mechanism and therapeutic effects:
- HbA1c: The primary glycemic monitoring marker for T2D and prediabetes management. Meaningful reductions are typically observed at 12 to 24 weeks of therapy. Baseline and follow-up HbA1c values quantify glycemic response. Reference ranges vary by lab and clinical context.
- Fasting glucose: A shorter-horizon glycemic marker than HbA1c. Useful at baseline to characterize glycemic status and at follow-up to track incremental changes. Fasting glucose is particularly informative in individuals in the prediabetes range (100-125 mg/dL).
- Fasting insulin: Semaglutide improves insulin sensitivity alongside direct effects on beta-cell insulin secretion. Baseline fasting insulin characterizes insulin resistance and provides context for subsequent glycemic changes.
- Lipid panel (LDL-C, triglycerides, HDL-C, non-HDL-C): Meta-analysis of STEP trials documents improvements in triglycerides, blood pressure, and lipid profiles alongside weight reduction. Baseline lipid assessment and follow-up at 3 to 6 months capture these cardiometabolic effects.
- hs-CRP: A sensitive systemic inflammation marker. Meta-analysis by Qin et al. (2023) documented significant reductions in hs-CRP with semaglutide 2.4 mg, suggesting anti-inflammatory effects beyond weight loss. Relevant for individuals with elevated baseline inflammatory status and cardiovascular risk.
- Complete metabolic panel (CMP): Covers liver function (AST, ALT) and kidney function (creatinine, BUN, eGFR). Semaglutide may produce modest improvements in eGFR in individuals with early renal impairment; baseline assessment is standard before initiation. An increased rate of biliary disease has been observed with weight loss and GLP-1 RA use; liver function monitoring is standard clinical practice.
- Complete blood count (CBC): Relevant at baseline to characterize overall health status and rule out underlying conditions that may affect tolerability assessment, including anemia, which can present with fatigue overlapping with common GI side effects.
- Blood pressure: STEP trial data document consistent reductions in systolic blood pressure alongside weight reduction. Tracking blood pressure before and during therapy quantifies this cardiometabolic effect, particularly relevant in the SELECT population with established cardiovascular disease.
- Thyroid function (TSH): GLP-1 receptor agonists carry a class-wide boxed warning regarding thyroid C-cell tumors observed in rodent studies. Baseline thyroid assessment may be relevant in individuals with pre-existing thyroid conditions or family history that warrants monitoring.
HbA1c, fasting glucose, fasting insulin, and a lipid panel are the core markers for evaluating cardiometabolic baseline before starting semaglutide. A complete metabolic panel confirms organ function. For individuals with established cardiovascular disease or elevated risk, a comprehensive cardiovascular biomarker assessment provides additional context that is particularly relevant given semaglutide's SELECT trial cardiovascular indication.
What Semaglutide Is Typically Prescribed For
Providers typically evaluate candidates for semaglutide based on FDA-approved indications: type 2 diabetes requiring glycemic management (Ozempic, Rybelsus); chronic weight management in adults with BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (Wegovy); and reduction of serious cardiovascular events in adults with established cardiovascular disease and overweight or obesity without T2D (Wegovy, SELECT indication). Baseline bloodwork confirming glycemic status, lipid profile, and organ function is standard practice before initiation. Semaglutide requires a prescription from a licensed provider.
Who Should Not Use Semaglutide
A licensed provider will evaluate individual risk factors before prescribing. The following are contraindications or conditions requiring additional clinical scrutiny based on the FDA prescribing information:
- Personal or family history of medullary thyroid carcinoma (MTC), as GLP-1 receptor agonists are associated with thyroid C-cell tumors in rodent studies; a boxed warning is required in all semaglutide prescribing information
- Multiple endocrine neoplasia syndrome type 2 (MEN 2), which includes elevated risk of MTC
- Known hypersensitivity to semaglutide or any component of the formulation; serious hypersensitivity reactions, including anaphylaxis, have been reported
- Pregnancy, as semaglutide may cause fetal harm based on animal data; adequate contraception is recommended during use and for a period following discontinuation per provider guidance
- Severe gastrointestinal disease, including gastroparesis, as semaglutide slows gastric emptying and may worsen underlying motility disorders
- History of pancreatitis, as GLP-1 receptor agonists have been associated with acute pancreatitis; while a direct causal relationship has not been conclusively established, the prescribing information advises caution and monitoring
- Diabetic retinopathy requiring treatment, as rapid glycemic improvement has been associated with early worsening of retinopathy in some patients
Side Effects and Safety Considerations
The most common side effects of semaglutide are gastrointestinal and are generally dose-dependent and most prominent during dose escalation. A safety analysis of the SELECT trial population published by Kushner and colleagues in Obesity in 2025, covering 17,604 participants receiving semaglutide 2.4 mg weekly or placebo over a mean of 39.8 months, found that serious adverse events were less frequent with semaglutide than placebo (33.4% vs 36.4%) while treatment discontinuation due to adverse events was higher with semaglutide (16.6% vs 8.2%, primarily driven by GI tolerability), confirming a favorable risk-benefit profile with no new safety concerns over nearly 40 months of follow-up.
Common (reported in clinical studies):
- Nausea (most common; a pooled analysis of STEP 1–3 participants receiving semaglutide 2.4 mg weekly reported nausea in 43.9% versus 16.1% with placebo, predominantly during dose escalation)
- Diarrhea (29.7% with semaglutide 2.4 mg vs 15.9% with placebo in the pooled STEP 1–3 analysis)
- Vomiting (24.5% with semaglutide 2.4 mg vs 6.3% with placebo in the pooled STEP 1–3 analysis)
- Constipation (24.2% with semaglutide 2.4 mg vs 11.1% with placebo in the pooled STEP 1–3 analysis)
- Injection-site reactions, including bruising, erythema, and pruritus at the injection site (mild and typically transient)
- Decreased appetite (a primary mechanism of action; expected and reported across trials)
- Abdominal pain and dyspepsia
Less common but reported:
- Acute pancreatitis: discontinue and contact your provider promptly if you experience severe, persistent abdominal pain radiating to the back
- Cholelithiasis (gallstones): an increased rate of biliary disease has been observed with weight loss and GLP-1 RA use; alert provider to right upper quadrant pain or jaundice
- Hypoglycemia: primarily in individuals using concurrent insulin or sulfonylureas; risk is low with semaglutide monotherapy
- Psychiatric symptoms: pharmacovigilance data published by Tobaiqy and colleagues in the International Journal of Clinical Pharmacy in 2024 reported psychiatric adverse events in 1.2% of all reports across GLP-1 RA class, with depression most common; alert provider to mood changes
- Hair loss (telogen effluvium): associated with rapid weight loss rather than direct drug effect; generally self-limiting within 3 to 6 months
- Increased heart rate: a modest increase in resting heart rate (approximately 2-4 bpm) has been observed across GLP-1 RA class; clinical significance in most patients is uncertain
Is Semaglutide Legal?
As of April 2026, semaglutide is FDA-approved for type 2 diabetes (Ozempic, Rybelsus), chronic weight management and cardiovascular risk reduction in adults with obesity and established cardiovascular disease (Wegovy). Semaglutide is not FDA-approved for any other indications. The safety and efficacy of semaglutide for any use other than the approved indications have not been established through adequate and well-controlled clinical trials reviewed by the FDA.
Compounded semaglutide has been available through 503A pharmacies. The FDA removed semaglutide from the shortage list in 2025, which changed the regulatory landscape for compounding of this compound under Section 503A and 503B. As of April 2026, providers should confirm current compounding status and regulatory requirements. Compounded semaglutide is not FDA-approved and has not undergone FDA review for safety, efficacy, or manufacturing quality. It is not available over the counter in any formulation.
Semaglutide does not appear on the 2026 WADA Prohibited List. Its approved indications are metabolic and cardiovascular, and it is not associated with athletic performance enhancement in the pharmacological sense covered by anti-doping regulations.
Understanding Your Baseline Before Starting Semaglutide
Semaglutide's effects on glycemia, weight, and cardiovascular risk markers are measurable — but only if there is a baseline to measure against. HbA1c and fasting glucose establish where glycemic control sits before therapy. Fasting insulin characterizes the degree of insulin resistance. A lipid panel captures the cardiometabolic context that determines whether the SELECT cardiovascular indication is clinically relevant. A metabolic panel rules out contraindications. Without these reference points, changes at 12, 24, and 52 weeks are interpretable only in isolation — not in the context of where the individual started.
That principle is central to Superpower's approach to preventive health: the belief that objective biomarker data should come before any clinical decision, and that every change during therapy should be interpretable against a documented baseline.
Frequently Asked Questions
What is the difference between semaglutide and tirzepatide?
Semaglutide activates GLP-1 receptors only. Tirzepatide activates both GLP-1 and GIP receptors. Tirzepatide has produced greater mean weight reduction and HbA1c lowering than semaglutide in comparative analyses at studied doses. Semaglutide has more extensive dedicated cardiovascular outcome trial data, including the SELECT trial (N=17,604). Both compounds carry similar gastrointestinal side effect profiles. The prescribing decision depends on individual clinical factors, indication, and provider evaluation.
Is semaglutide the same as Ozempic?
Ozempic is a brand-name subcutaneous formulation of semaglutide (0.5 mg, 1.0 mg, 2.0 mg once weekly) approved for type 2 diabetes and cardiovascular risk reduction in T2D patients. Wegovy is a higher-dose subcutaneous semaglutide formulation (escalating to 2.4 mg weekly) approved for weight management and cardiovascular risk reduction in adults with obesity without T2D. Rybelsus is an oral semaglutide tablet approved for type 2 diabetes. All three contain the same active molecule; they differ in dose, route, and FDA indication.
What happens to your body when you stop semaglutide?
Weight regain is well-documented after discontinuation. In the STEP 1 trial extension following 327 participants who discontinued semaglutide 2.4 mg weekly after 68 weeks, participants regained 11.6 percentage points of lost weight — approximately two-thirds of the initial reduction — within 52 weeks of stopping treatment, and most cardiometabolic improvements also reversed. This reflects the ongoing hormonal nature of GLP-1 pathway modulation; the effects are not permanent. Providers typically discuss long-term maintenance strategies before initiating therapy.
How much weight can you lose on semaglutide in 3 months?
In the STEP 1 trial (N=1,961), participants taking semaglutide 2.4 mg once weekly achieved 14.9% mean weight reduction over 68 weeks versus 2.4% with placebo; weight loss was progressive throughout the treatment period, with the majority occurring between weeks 12 and 68 during dose escalation and maintenance. The trial did not report a standalone 12-week interim analysis, and early results during the dose-escalation phase may not reflect the full treatment effect. Individual results varied substantially across trial participants. Dietary and lifestyle changes concurrent with medication use were part of the trial protocol.
Can you take semaglutide without being diabetic?
Yes. Semaglutide (as Wegovy) is FDA-approved for chronic weight management in adults without type 2 diabetes who have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity. The STEP 1 trial specifically enrolled participants without T2D and demonstrated 14.9% mean weight loss at 68 weeks. Additionally, the SELECT trial enrolled non-diabetic adults with established cardiovascular disease and overweight or obesity, supporting the 2024 cardiovascular risk reduction indication for Wegovy.
Is compounded semaglutide the same as brand-name?
No. Compounded semaglutide is not FDA-approved and has not undergone FDA review for quality, potency, or sterility. Compounded medications are prepared by a licensed compounding pharmacy and may differ from branded formulations in formulation, concentration, and inactive ingredients. The FDA removed semaglutide from the shortage list in February 2025, which changed the regulatory landscape for compounding. A licensed provider can clarify current regulatory status and available options.
Does semaglutide cause hair loss?
Hair thinning associated with semaglutide is attributed to what research suggests is telogen effluvium, a diffuse shedding response to significant physiological stress, including rapid weight loss. It is not considered a direct pharmacological drug effect. It was reported at low rates in STEP trial data. Telogen effluvium is generally self-limiting and resolves within 3 to 6 months as body weight stabilizes. Adequate protein intake and overall nutritional adequacy during weight loss are clinically relevant to minimize hair follicle disruption.
Is semaglutide FDA-approved?
Yes. Semaglutide is FDA-approved under three brand names for four indications: Ozempic for type 2 diabetes (2017) and cardiovascular risk reduction in T2D patients with established heart disease (2020); Rybelsus (oral) for type 2 diabetes (2019); and Wegovy for chronic weight management (2021) and for reducing serious cardiovascular events in adults with obesity and established cardiovascular disease without T2D under the 2024 SELECT indication. No other uses have been approved by the FDA.
IMPORTANT SAFETY INFORMATION
Semaglutide is an FDA-approved prescription medication marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral, type 2 diabetes). The compounded formulation available through Superpower is NOT the FDA-approved drug product. Compounded semaglutide has not been reviewed by the FDA for safety, efficacy, or manufacturing quality. Clinical trial results cited on this page were generated using FDA-approved branded formulations and may not apply to compounded versions. The availability of compounded semaglutide is subject to ongoing regulatory developments regarding drug shortage status. Superpower is a technology platform that connects you with licensed providers and pharmacies; Superpower does not prescribe or dispense medications.
Boxed warning (from FDA-approved labeling): Semaglutide causes thyroid C-cell tumors in rodents. It is unknown whether it causes medullary thyroid carcinoma (MTC) in humans. Do not use if you or any family member has had MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Do not use if you: have a personal or family history of MTC or MEN 2; have had a serious allergic reaction to semaglutide.
Warnings: pancreatitis, gallbladder events, hypoglycemia (with insulin/sulfonylureas), kidney injury, serious allergic reactions, diabetic retinopathy complications, gastroparesis/delayed gastric emptying, suicidal ideation (reported with GLP-1 medications).
Common side effects: nausea, vomiting, diarrhea, stomach pain, constipation, fatigue, headache.
Pregnancy: not recommended. Discontinue at least 2 months before a planned pregnancy.
Not a complete list of risks. Full FDA-approved prescribing information at dailymed.nlm.nih.gov.
.avif)
.avif)
.avif)
.avif)
.avif)
.jpg)
.avif)
